FDA Accepts ImmunityBio’s Bladder Cancer Candidate For Review
[ad_1] The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s IBRX Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with BCG-unresponsive non-muscle-invasive…
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
[ad_1] Turning Point Therapeutics TPTX has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter. The pre-NDA…